Efficacy of continuous zanubrutinib monotherapy versus fixed-duration acalabrutinib plus venetoclax or venetoclax plus obinutuzumab in treatment-naïve chronic lymphocytic leukemia: a network meta-analysis

Authors

Institutions

Publication Details

Journal
Leukemia & lymphoma/Leukemia and lymphoma
Published
2026-11-11
DOI
https://doi.org/10.1080/10428194.2026.2722721
Primary Topic
Chronic Lymphocytic Leukemia Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Efficacy of continuous zanubrutinib monotherapy versus fixed-duration acalabrutinib plus venetoclax or venetoclax plus obinutuzumab in treatment-naïve chronic lymphocytic leukemia: a network meta-analysis

Talha Munir, Sheng Xu, Rhys Williams, Mazyar Shadman et al.
Leukemia & lymphoma/Leukemia and lymphoma
Chronic Lymphocytic Leukemia Research
article

Efficacy of continuous zanubrutinib monotherapy versus fixed-duration acalabrutinib plus venetoclax or venetoclax plus obinutuzumab in treatment-naïve chronic lymphocytic leukemia: a network meta-analysis

Talha Munir, Sheng Xu, Rhys Williams, Mazyar Shadman, Keri Yang
article en

Abstract

No abstract available for this paper.
Leukemia & lymphoma/Leukemia and lymphoma
University of Washington (US), Leeds Teaching Hospitals NHS Trust (GB), Fred Hutch Cancer Center (US), BeOne Medicines (Switzerland) (CH)
Chronic Lymphocytic Leukemia Research
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon